STOCK TITAN

Cymabay Therapeu Stock Price, News & Analysis

CBAY Nasdaq

Welcome to our dedicated page for Cymabay Therapeu news (Ticker: CBAY), a resource for investors and traders seeking the latest updates and insights on Cymabay Therapeu stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cymabay Therapeu's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cymabay Therapeu's position in the market.

Rhea-AI Summary

CymaBay Therapeutics (Nasdaq: CBAY) is hosting its 2020 Annual Meeting of Stockholders virtually on June 23, 2020, at 10:00 a.m. Pacific Time. This decision results from public health concerns related to the COVID-19 pandemic. Stockholders can participate via live audio webcast, ensuring equal opportunity for interaction. Voting and question submissions will be available electronically using a 16-digit control number. The company encourages early voting and proxy submissions to ensure participation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
-
Rhea-AI Summary

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced a conference call on May 11, 2020, at 4:30 p.m. ET to discuss its financial results for Q1 2020, which ended on March 31, 2020. The call will provide an update on the company's business as it focuses on developing therapies for liver and other chronic diseases.

Investors can access the call by dialing specific numbers provided or through the company's website for a live and archived audio webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences earnings

CBAY Rankings

CBAY Stock Data

110.08M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newark

CBAY RSS Feed